Form 8-K - Current report:
SEC Accession No. 0001104659-16-153912
Filing Date
2016-11-02
Accepted
2016-11-02 07:00:44
Documents
5
Period of Report
2016-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a16-20876_18k.htm 8-K 25891
2 EX-99.1 a16-20876_1ex99d1.htm EX-99.1 93273
3 GRAPHIC g208761mmi001.jpg GRAPHIC 3087
4 GRAPHIC g208761mmi002.jpg GRAPHIC 3087
5 GRAPHIC g208761mmi003.jpg GRAPHIC 3091
  Complete submission text file 0001104659-16-153912.txt   133515
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 161966266
SIC: 2834 Pharmaceutical Preparations